Cohance Lifesciences Delivers Strong Q4 Finish With Robust Revenue Momentum

Nikunj Parikh May 12, 2026 290 Views

Cohance Lifesciences has reported a consolidated net profit of 195.5 million rupees and revenue from operations of 6.19 billion rupees for the March 2026 quarter (Q4 FY26), underscoring healthy earnings traction, strong topline growth and improving scale in its speciality pharma and CDMO-focused lifesciences platform.